Eculizumab for the Treatment of Dense-Deposit Disease

the experimental data showing that either C5 gene deletion or anti-C5 antibodies ameliorate kidney disease in complement factor H-deficient mice with disease that is similar to dense-deposit disease. 5 We are aware of two other patients with dense-deposit disease who have received eculizumab (Smith RJH: personal communication).One patient, with high sC5b-9 levels, showed a good clinical response, whereas the other, who had normal sC5b-9 levels, did not benefit.We speculate that following sequential blood sC5b-9 levels might help in predicting the response to eculizumab in dense-deposit disease.